The healthcare landscape is undergoing a profound transformation, with genomics emerging as a cornerstone of a more personalized and preventive future. The global precision medicine market, driven by advancements in sequencing technologies, decreasing sequencing costs, and a societal shift towards personalized health, is projected to reach $469 billion by 2034.
At the forefront of this evolution is InformedDNA, a company dedicated to the applied use of genomics. Its mission is to harness the full potential of genomics within precision medicine to improve the health of the general population. This strategic focus positions InformedDNA not only as a participant in the genomics revolution but also as a crucial enabler of its practical and widespread adoption.
By concentrating on translating existing and emerging genomic knowledge into routine clinical practice, the company addresses a critical gap: making the promise of genomic medicine a tangible reality for patients, providers, and payors.
Unlocking the Potential of Applied Genomics
Leading this effort is Dr. Surya Singh, InformedDNA’s CEO and a physician with deep experience across large corporations, entrepreneurial ventures, and clinical practice. His passion lies in translating genomics into real-world population health management.
InformedDNA specializes in applying genomics broadly—from identifying hereditary disease risks to optimizing medication prescriptions through pharmacogenomics. “Genomics includes how our genes interact and cause different diseases, and the variations in how we process drugs,” explains Dr. Singh.
The company addresses both the underutilization of validated genetic markers and the overutilization of unnecessary genetic testing, ensuring precise and cost-effective genomic healthcare.
Dr. Singh emphasizes that physicians and other clinicians must move beyond oncology and rare diseases when considering the practical use of genetics or genomics in practice: “We need to start having people think about mental health, cardiac disease, and other common chronic conditions when they consider genetics.”
DNAimpact: A Digital-First Solution
Central to InformedDNA’s strategy is DNAimpact, its flagship population health support platform launched to integrate genomic insights into everyday medicine. One of its key design principles is to integrate genetic testing, patient engagement, education, and counseling into one cohesive platform. This digital-first model ensures accessibility and proactive patient management, enabling real-time, personalized health insights.
“DNAimpact is digital-first,” Dr. Singh explains. “We’ve already analyzed your clinical data to identify relevant genetic tests. We then digitally engage patients, offer simple online assessments, and provide interactive reports and expert consultations.”
DNAimpact emphasizes three core areas:
Pharmacogenomics (DNAimpact Rx): Optimizes medication selection and dosing based on each individual’s genetic profile, significantly reducing adverse reactions and enhancing drug efficacy.
Hereditary Cancer Screening: Identifies genetic predispositions to cancers such as breast and colorectal, guiding personalized preventive care and screenings.
Hereditary Cardiac Disease Management: Assesses genetic risk for cardiac conditions, enabling targeted interventions.
Each patient receives clear, actionable reports and direct access to genetic counselors and specialized pharmacists. “It’s not just a confusing report,” Dr. Singh says. “We explain every result clearly, digitally, and live, ensuring actionable insights.”
The selection of these focus areas—pharmacogenomics for common medications, prevalent cancer risks, and hereditary cardiac conditions—is highly strategic. These conditions represent some of the most significant burdens on the healthcare system, with an estimated 129 million people in the United States having at least one major chronic disease.
By targeting areas with high prevalence and significant cost implications, DNAimpact offers a clear value proposition to employers and health plans, who bear a substantial portion of these costs. This focus aligns with oncology and pharmacogenomics being identified as key application areas within the broader precision medicine market.
Enhancing Everyday Medical Decisions with Genomics
Pharmacogenomics exemplifies how genomics can dramatically improve routine healthcare decisions. Dr. Singh highlights a recent pilot program demonstrating powerful results:
“Two-thirds of tested individuals needed medication modifications based on genetic profiles. About 87% of those followed our recommendations, improving patient outcomes substantially, both in terms of adverse event prevention and efficacy.”
InformedDNA’s recent acquisition of Coriell Life Sciences further strengthens its pharmacogenomic capabilities, incorporating robust historical data showing consistent, positive patient outcomes.
“Across multiple populations, almost all program participants had findings relevant to current or potential future treatments for existing clinical diagnoses based on their genetic profiles,” Dr. Singh notes, underscoring the universal applicability of genomic insights.
Navigating Provider Challenges in Genetic Testing
Despite the proven benefits, providers often struggle with genomic testing due to the overwhelming number of options and the complexity of their interpretations.
“There are too many tests available, making selecting the right one for each individual challenging,” says Dr. Singh. Additionally, interpreting the complicated lab reports is too time-consuming and sits outside of clinical workflows.”
For example, a cardiologist may receive a 17-page pharmacogenomics report for a patient, but lack the time or specialty knowledge to interpret complex drug-gene interactions. InformedDNA’s streamlined reports and on-call genetic experts make this process manageable and actionable.
“We simplify and clarify genomic test results, offering clinicians precise, actionable guidance,” says Dr. Singh. “Providers appreciate the ease of interpretation and immediate access to experts.”
Engaging Payors as Essential Partners
Payors play a pivotal role in the adoption and success of genomic healthcare solutions. According to Dr. Singh, payors are instrumental in selecting populations for genetic testing, monitoring program performance, and guiding future healthcare innovations. Their involvement ensures genomic initiatives align with population needs and demonstrate measurable returns on investment.
“Payors contribute significantly by collaborating closely with healthcare providers and genetic specialists to pinpoint areas with the greatest need for genomic interventions. This partnership helps direct resources efficiently, minimizing unnecessary expenditures and maximizing the health outcomes for targeted populations,” he adds.
Furthermore, payors play an essential role in assessing the financial sustainability of genomic programs. They scrutinize detailed analytics on patient outcomes, medication adjustments, and preventive interventions to ensure that genomic solutions deliver tangible economic value alongside health improvements.
“The ongoing dialogue with payors provides invaluable feedback loops that refine our strategies and foster continuous improvement, ultimately benefiting patients, providers, and the broader healthcare system,” says Dr. Singh.
Overcoming Barriers to Adoption
While genomic healthcare holds significant promise, systemic inertia and the proliferation of tests remain significant obstacles. Dr. Singh outlines these barriers clearly: “Healthcare systems are inherently slow to integrate new practices. Additionally, the growing number of genetic tests complicates adoption.”
InformedDNA is actively mitigating these challenges through targeted provider education, clear clinical decision-support tools, and robust evidence of cost-effectiveness and improved patient outcomes. Importantly, the company also helps ensure that genomic testing is applied appropriately—closing gaps where validated tests are underutilized while also helping prevent the overuse of expensive, unnecessary testing.
“We provide clear, evidence-based tools and counseling to ease the integration of genomics into routine care,” Dr. Singh says.
The Future of Genomics in Preventive Care
Looking forward, genomics promises a healthcare system that’s increasingly preventive, precise, and cost-effective.
InformedDNA, through its innovative DNAimpact platform and comprehensive service model, is playing a crucial role in making sophisticated genomic information more accessible, understandable, and actionable for a wide array of stakeholders.
The company’s efforts extend beyond simply offering tests; they encompass education, expert interpretation, and seamless integration into care pathways. By systematically breaking down barriers and showcasing measurable successes, the company is leading the charge toward a future where personalized medicine is the norm rather than the exception.
“Precision health, and, specifically, the targeted use of genetics and genomics will continue to drive an increasing and meaningful improvement in clinical outcomes across multiple specialty areas,” says Dr. Singh. “As testing becomes cheaper and expert interpretation of this testing more accessible, thoughtful integration of precision health-oriented solutions will increase the value delivered to individuals and populations via better outcomes, higher patient satisfaction, and reduced healthcare costs.”
Learn more at www.InformedDNA.com.
Daniel Casciato is a seasoned healthcare writer, publisher, and product reviewer with two decades of experience. He founded Healthcare Business Today to deliver timely insights on healthcare trends, technology, and innovation. His bylines have appeared in outlets such as Cleveland Clinic’s Health Essentials, MedEsthetics Magazine, EMS World, Pittsburgh Business Times, Post-Gazette, Providence Journal, Western PA Healthcare News, and he has written for clients like the American Heart Association, Google Earth, and Southwest Airlines. Through Healthcare Business Today, Daniel continues to inform and inspire professionals across the healthcare landscape.
